These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35871712)

  • 1. Oral antiviral treatments for COVID-19: opportunities and challenges.
    Rahmah L; Abarikwu SO; Arero AG; Essouma M; Jibril AT; Fal A; Flisiak R; Makuku R; Marquez L; Mohamed K; Ndow L; Zarębska-Michaluk D; Rezaei N; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1255-1278. PubMed ID: 35871712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
    J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-generation oral antivirals against SARS-CoV-2.
    Sendi P; Razonable RR; Nelson SB; Soriano A; Gandhi RT
    Clin Microbiol Infect; 2022 Sep; 28(9):1230-1235. PubMed ID: 35545195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
    Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.
    Dal-Ré R; Becker SL; Bottieau E; Holm S
    Lancet Infect Dis; 2022 Aug; 22(8):e231-e238. PubMed ID: 35364019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.
    Soriano V; de-Mendoza C; Edagwa B; Treviño A; Barreiro P; Fernandez-Montero JV; Gendelman HE
    AIDS Rev; 2022 Mar; 24(1):41-49. PubMed ID: 35073629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea.
    Jeon J; Chin B
    J Korean Med Sci; 2022 Dec; 37(48):e352. PubMed ID: 36513054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral drugs against SARS-CoV-2.
    Aiello TF; García-Vidal C; Soriano A
    Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):10-15. PubMed ID: 36285850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders.
    Ouyang J; Zaongo SD; Harypursat V; Li X; Routy JP; Chen Y
    Front Public Health; 2022; 10():945448. PubMed ID: 36003629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic developments for SARS-CoV-2 infection-Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice.
    Săndulescu O; Apostolescu CG; Preoțescu LL; Streinu-Cercel A; Săndulescu M
    Front Microbiol; 2023; 14():1132501. PubMed ID: 36937282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pandemic COVID-19, an update of current status and new therapeutic strategies.
    Vitiello A; La Porta R; Trama U; Ferrara F; Zovi A; Auti AM; Di Domenico M; Boccellino M
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1159-1165. PubMed ID: 35779085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea.
    Jo Y; Kim SB; Radnaabaatar M; Huh K; Yoo JH; Peck KR; Park H; Jung J
    Epidemiol Health; 2022; 44():e2022034. PubMed ID: 35381167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.